SCHEMBL3709876

SCHEMBL3709876

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1cccnc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.74
RXFP1 Q9HBX9 4/20 0.74
NPSR1 Q6W5P4 3/20 0.74
KDM4E B2RXH2 6/20 0.72
PKM P14618 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
FPR1 P21462 1/20 0.59
LMNA P02545 2/20 0.58
ALOX15 P16050 2/20 0.58
HPGD P15428 1/20 0.58
TDP1 Q9NUW8 1/20 0.57
POLB P06746 2/20 0.55
TSHR P16473 1/20 0.54
MAPT P10636 1/20 0.53
HTT P42858 1/20 0.53
PPARG P37231 2/20 0.52
NCOR2 Q9Y618 2/20 0.52
NCOA2 Q15596 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3709481 0.87 ALDH1A1 (0.66) ALDH1A1RXFP1NPSR1KDM4EPKM
SCHEMBL3715636 0.87 ALDH1A1 (0.61) ALDH1A1RXFP1NPSR1KDM4EPKM
SCHEMBL3705035 0.82 KDM4E (0.66) ALDH1A1RXFP1KDM4EPKMSMN1; SMN2
SCHEMBL16904821 0.81 KDM4E (0.64) ALDH1A1RXFP1KDM4EFPR1LMNA
SCHEMBL3707576 0.81 KDM4E (0.64) ALDH1A1RXFP1KDM4EFPR1LMNA
SCHEMBL3705340 0.80 MEN1 (0.78) ALDH1A1RXFP1KDM4EFPR1LMNA
SCHEMBL3713778 0.80 KDM4E (0.63) ALDH1A1RXFP1KDM4EFPR1LMNA
SCHEMBL3707111 0.80 SMN1; SMN2 (0.55) ALDH1A1RXFP1NPSR1KDM4ESMN1; SMN2
SCHEMBL3712867 0.80 ALDH1A1 (0.54) ALDH1A1RXFP1NPSR1KDM4EPKM
SCHEMBL3714770 0.79 HPGD (0.67) ALDH1A1RXFP1NPSR1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed